Pharmafile Logo

News and Press Releases

Samsung Bioepis Begins Commercialization of BYOOVIZ, Biosimilar to Lucentis (Ranibizumab), in Europe

Samsung Bioepis completes full transfer of commercial rights from Biogen back to Samsung Bioepis for BYOOVIZ BYOOVIZ becomes the fourth biosimilar directly commercialized by Samsung Bioepis in Europe, following EPYSQLI...

Category: Logistics, Other, Pharmaceutical
Posted: January 2, 2026

Eisai presents 4-year Leqembi (lecanemab) open-label extension data from post-hoc sub-group analysis at German neurology congress

Clarity AD open-label extension data show that after four years of continuous lecanemab treatment in apolipoprotein E ε4 (ApoE ε4*) non-carriers and heterozygotes, patients continued to accrue benefit relative to...

Category: Clinical Trials, Other, Pharmaceutical
Posted: November 12, 2025

Eisai
4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan

Leqembi (lecanemab) long-term 36-month open-label extension data from post-hoc sub-group analysis of ApoE ε4 non-carriers and heterozygotes presented at Alzheimer’s disease congress in Switzerland

Clarity AD open-label extension data show three years of continuous lecanemab treatment in apolipoprotein E ε4 (ApoE ε4) non-carrier and heterozygote patients continued to accrue benefit relative to the Alzheimer's...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: September 29, 2025

Eisai
4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan

Leqembi® (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorised in the European Union           

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 16, 2025

Eisai
4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan

Patients Most In Need Face Obstacles to Participating in Life-Saving Clinical Trials According to a New Milken Institute Report

24 June 2024 -- Washington, DC -- Clinical trials can provide the possibility to obtain novel treatments for conditions and diseases that are not yet commercially available. Yet, these lifesaving...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 24, 2024

Milken Institute
inquiries@milkeninstitute.org
730 15th Street NW Washington, DC 20005

Biogen Receives European Commission Approval for QALSODY (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS

SOD1-ALS is a devastating, uniformly fatal and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe QALSODY is Biogen’s third rare disease therapy to be...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: May 30, 2024

Biogen
Biogen International GmbH Neuhofstrasse 30 6340 Baar Switzerland

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseases Felzartamab is an investigational anti-CD38 monoclonal antibody that, through its...

Category: Drug Discovery, Pharmaceutical
Posted: May 22, 2024

Biogen
Biogen International GmbH Neuhofstrasse 30 6340 Baar Switzerland

National Minority Quality Forum And Biogen Release a Report Highlighting a Model to Improve Clinical Trial Diversity

Partnership works to improve outcomes for Black and Hispanic women living with lupus 20 May 2024 -- Washington, DC -- The National Minority Quality Forum and Biogen released a report, Improving Diversity in Clinical Trials,...

Category: Clinical Trials, Other
Posted: May 20, 2024

National Minority Quality Forum
infodesk@nmqf.org
1201 15th Street, NW, Suite 340 Washington, DC, 20005